New market study, "Malaysia Pharmaceuticals & Healthcare Report Q2 2015", has been published

From: Fast Market Research, Inc.
Published: Mon Apr 06 2015

Malaysia's 2015 budget reinforces our upbeat outlook on the country's pharmaceutical market. Rising healthcare expenditure plans to improve medical access and efforts to mitigate the impact of the Goods and Service Tax on medicine prices will provide companies with significant revenue - earn ing opportunities. However, downside risks to our outlook include further economic slowdown forecast for 2015, worries of an increasing number of imitation drugs and growing political differences within both the o pposition and ruling coalitions.

Headline Expenditure Projections

* Pharmaceuticals: MYR6.60bn (USD2.10bn) in 2013 to MYR7.22bn (USD2.25bn) in 2014; +9.3 % in local currency and +7.6% in US dollar terms. Forecast revised down from last quarter to better suit current market conditions.
* Healthcare: MYR40.27bn (USD12.78bn) in 2013 to MYR43.79bn (USD13.68bn) in 2014; +8.7% in local currency and +7.1% in US dollar terms. Forecast unchanged from last quarter's figures.

Full Report Details at

Risk/Reward Index : Malaysia's Pharmaceutical Risk/Reward Index (RRI) score for Q115 is 58.9 out of 100, making it the eighth most attractive pharmaceutical market in the Asia Pacific region. It posts above-average scores for every indicator.

Key Trends And Developments

In November 2014, Health Minister Dr Subramaniam stated that Malaysia attracted over 770,000 foreigners seeking healthcare at the country's private hospitals in 2013, with Indonesians accounting for around 56.76% of the total. The number of Indonesians travelling for healthcare to Malaysia stood at over 437,000: more than 27,000 Indians, about 22,300 Japanese and 21,000 Chinese people. The country also recorded health tourism from other nations, including Libya (about 19,000), Britain (17,000), Australia (13,300), the US (12,300), Bangladesh (about 12,000) and the Philippines (10,500). About 95 foreign medical specialists, including 18 female specialists, were practicing in Malaysia as of the end of September 2014.

Register for full summary


The Malaysia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysia pharmaceutical and healthcare industry.

Key Benefits

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015
- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »